New selective inhibitors of steroid 11β-hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues

Journal of Medicinal Chemistry

Volumn 51, Issue 7, 2008, Pages 2244-2253

  Zolle, Ilse M ^a   Berger, Michael L ^b   Hammerschmidt, Friedrich ^a   Hahner, Stefanie ^c   Schirbel, Andreas ^c   Peric Simov, Biljana ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Medical University of Vienna   (Austria)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 FLUOROETHYL ESTER; 3 PYRIDYL METOMIDATE; 4 IODO METOMIDATE; ACETONE; DEMETHYL METOMIDATE; ETOMIDATE; IODINE 131; IODOPHENYL METOMIDATE; METOMIDATE; N METHOXYAMIDE; N METHYLAMIDE; RADIOISOTOPE; RADIOLIGAND; STEROID 11BETA MONOOXYGENASE; UNCLASSIFIED DRUG;

ADRENAL CORTEX; ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG BINDING; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN;

ADRENAL CORTEX; ANIMALS; BINDING SITES; ETOMIDATE; HUMANS; HYDROXYLATION; IODINE RADIOISOTOPES; KINETICS; MALE; MOLECULAR STRUCTURE; RATS; RATS, WISTAR; STEREOISOMERISM; STEROID 11-BETA-HYDROXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41849083040     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800012w     Document Type: Article

References (58)

1. Fellows, I. W.; Bastow, M. D.; Byrne, A. J.; Allison, S. P. Adreno-cortical suppression in multiply injured patients: a complication of etomidate treatment. Br. Med. J. 1983, 287, 1835-1837.
2. Drake, W. M.; Perry, L. A.; Hinds, C. J.; Lowe, D. G.; Reznek, R. H.; Besser, G. M. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. J. Clin. Endocrinol. Metab. 1998, 83, 3542-3544.
3. Vanden Bossche, H.; Willemsens, G.; Cools, W.; Bellens, D. Effects of etomidate on steroid biosynthesis in subcellular fractions of bovine adrenals. Biochem. Pharmacol. 1984, 33, 3861-3868.
4. The European Pharmacopeia 5.0; Etomidate, Monograph 1514; Council of Europe, Maisonneuve: Sainte-Ruffine, France, 2005.
5. Satre, M.; Vignais, P. V.; Idelman, S. Distribution of the steroid 11β-hydroxylase and the cytochrome P-450 in membranes of beef adrenal cortex mitochondria. FEBS Lett. 1969, 5, 135-140.
6. 3H]metyrapol, an inhibitor for the 11β-hydroxylation reaction. Biochemistry 1974, 13, 2201-2209.
7. Yago, N.; Ichii, S. Submitochondrial distribution of components of the steroid 11β-hydroxylase and cholesterol sidechain-cleaving enzyme systems in hog adrenal cortex. J. Biochem. (Tokyo) 1969, 65, 215-224.
8. Dodge, A. H.; Christensen, A. K.; Clayton, R. B. Localization of steroid 11 beta-hydroxylase in the inner membrane subfraction of rat adrenal mitochondria. Endocrinology 1970, 87, 254-261.
9. Young, D. G.; Hall, P. F. Steroid hydroxylation in bovine adrenocortical mitochondria. Competition between side-chain cleavage of cholesterol and 11β-hydroxylation. Biochemistry 1971, 10, 1496-1502.
10. Wilson, L. D.; Harding, B. W. Oxidation of 20α-hydroxycholesterol by adrenal cortex mitochondria. J. Biol. Chem. 1973, 248, 9-14.
11. Engelhardt, D. Steroid biosynthesis inhibitors in Cushing's syndrome. Clin. Invest. 1994, 72, 481-488.
12. Napoli, J. L.; Counsell, R. E. New inhibitors of steroid 11β-hydroxylase. Structure-activity relationship studies of metyrapone-like compounds. J. Med. Chem. 1977, 20, 762-766.
13. Hays, S. J.; Tobes, M. C.; Gildersleeve, D. L.; Wieland, D. M.; Beierwaltes, W. H. Structure-activity relationship study of the inhibition of adrenal cortical 11β-hydroxylase by new metyrapone analogues. J. Med. Chem. 1984, 27, 15-19.
14. Zolle, I.; Woloszczuk, W.; Höfer, R. Synthesis and in Vitro Evaluation of Metyrapone Derivatives as Potential Inhibitors of 11β-Hydroxylase Activity. In Radiopharmaceuticals and Labelled Compounds 1984, Proceedings Series, IAEA-CN-45/67; International Atomic Energy Agency: Vienna, Austria, 1985; pp 337-342.
15. Damani, L. A.; Mitterhauser, M.; Zolle, I.; Lin, G.; Oehler, E.; Ho, Y.-P. Metabolic and pharmacokinetic considerations in the design of 2-phenyl substituted metyrapone derivatives: 2-methoxyphenylmetyrapone as a radioligand for functional diagnosis of adrenal pathology. Nucl. Med. Biol. 1995, 22, 1067-1074.
16. Wieland, D. M.; Ice, R. D.; Beierwaltes, W. H. Synthesis of radiolabeled enzyme inhibitors of the adrenal cortex. J. Nucl. Med. 1976, 17, 525.
17. Beierwaltes, W. H.; Wieland, D. M.; Ice, R. D.; Seabold, J. E.; Sarkar, S. D.; Gill, S. P.; Mosley, S. T. Localization of radiolabeled enzyme inhibitors in the adrenal gland. J. Nucl. Med. 1976, 17, 998-1002.
18. Beierwaltes, W. H.; Wieland, D. M.; Mosley, S. T.; Swanson, D. P.; Sarkar, S. D.; Freitas, J. E.; Thrall, J. H; Herwig, K. R. Imaging the adrenal glands with radiolabeled inhibitors of enzymes: concise communication. J. Nucl. Med. 1978, 19, 200-203.
19. Robien, W.; Zolle, I. Synthesis of radioiodinated metyrapone - a potential adrenal imaging agent. Int. J. Appl. Radiat. Isot. 1983, 34, 907-914.
20. Hays, S. J.; Mangner, T. J. Synthesis of iodine-125 labelled analogues of metyrapone and metyrapol. J. Labelled Compd. Radiopharm. 1983, XX, 1373-1381.
21. 11C]-2- Methoxyphenylmetyrapone for PET. J. Labelled Compd. Radiopharm. 1993, XXXII, 547-549.
22. Yu, J.; Mertens, J.; Rakias, F.; Zolle, I. Synthesis of radio-2-iodophenylmetyrapone using Cu(I)-assisted nucleophilic exchange labelling: study of the reaction kinetics. Nucl. Med. Biol. 1995, 22, 257-262.
23. 3H]Metyrapol as a tool for studies of interactions of deoxycorticosterone with adrenal cortex mitochondria. FEBS Lett. 1972, 26, 193-196.
24. Berger, M. L.; Hahner, S.; Hammerschmidt, F.; Schirbel, A.; Yu, J.; Zolle, I. Inhibitors of Adrenal P-450c11 Hydroxylase Characterized by Two Radioligands and Steroid Hormone Secretion. Presented at the International Symposium on Trends in Radiopharmaceuticals (IAEA), Vienna, Austria, November 14-18, 2005.
25. Berger, M. L.; Schirbel, A.; Hammerschmidt, F.; Zolle, I. Structural requirements of metomidate for high affinity binding to adrenal membranes. Eur. J. Nucl. Med. Mol. Imaging 2002, 29 (Suppl. 1), S380.
26. 123/131I]Iodometomidate as a radio-ligand for functional diagnosis of adrenal disease: synthesis, structural requirements and biodistribution. Radiochim. Acta 2004, 92, 297-303.
27. Bergström, M.; Bonasera, T. A.; Lu, L.; Bergström, E.; Backlin, C.; Juhlin, C.; Långström, B. In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J. Nucl. Med. 1998, 39, 982-989.
28. 11C-metomidate. J. Nucl. Med. 2000, 41, 275-282.
29. 18F]FETO, a novel potential 11β-hydroxylase inhibitor. J. Labelled Compd. Radiopharm. 2003, 46, 379-388.
30. Godefroi, E. F.; Janssen, P. A. J.; Van der Eycken, C. A. M.; Van Heertum, A. H. M. T.; Niemegeers, C. J. E. D,L-1-(1-Arylalkyl) imidazole-5-carboxylate esters. A novel type of hypnotic agents. J. Med. Chem. 1965, 8, 220-223.
31. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981, 1-28.
32. Roevens, L. F. C.; Heykants, J. J. P.; Helsen, W. A. M. (Janssen Pharmaceutica, N.V.) 1-1-Phenylethyl)-1H-imidazole-5-carboxylic Acid Esters, Their Enantiomers and Acid Salts. Ger. 2,609,573 (C1.C07D233/90), September 30, 1976; U.S. Appl. 557,194, March 10, 1975; Chem. Abstr. 1976, 85, 192739x.
33. Hughes, D. L. The Mitsunobu Reaction. Org. React. 1992, 42, 335-656.
34. Nahm, S.; Weinreb, S. M. N-Methoxy-N-methylamides as effective acylating agents. Tetrahedron Lett. 1981, 22, 3815-3818.
35. Corelli, F.; Summa, V.; Brogi, A.; Monteagudo, E.; Botta, M. Chiral azole derivatives. 2. Synthesis of enantiomerically pure 1-alkylimidazoles. J. Org. Chem. 1995, 60, 2008-2015.
36. Hammerschmidt, F.; Peric Simov, B.; Schmidt, S.; Schneider, S.; Zolle, I. Chemoenzymatic synthesis of stannylated metomidate as a precursor for electrophilic radiohalogenations - regioselective alkylation of methyl 1H-imidazole-5-carboxylate. Monatsh. Chem. 2005, 136, 229-239.
37. Laumen, K.; Schneider, M. P. A highly selective ester hydrolase from Pseudomonas sp. for the enzymatic preparation of enantiomerically pure secondary alcohols; chiral auxiliaries in organic synthesis. J. Chem. Soc., Chem. Commun. 1988, 598-600.
38. Seemayer, R.; Schneider, M. P. Preparation of optically pure pyridyl-1-ethanols. Tetrahedron: Asymmetry 1992, 3, 827-830.
39. Baillargeon, V. P.; Stille, J. K. Palladium-catalyzed formylation of organic halides with carbon monoxide and tin hydride. J. Am. Chem. Soc. 1986, 108, 452-461.
40. Godefroi, E. F.; Van Cutsem, J.; Van der Eycken, C. A. M.; Janssen, P. A. J. 1-(1-Indanyl)- and 1-(1-tetralyl)imidazole-5-carboxylate esters, a novel type of antifungal agents. J. Med. Chem. 1967, 10, 1160-1161.
41. Lamberts, S. W. J.; Bons, E. G.; Bruining, H. A.; De Jons, F. H. Differential effects of imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J. Pharmacol. Exp. Therap. 1987, 240, 259-264.
42. Murray, M.; Reidy, G. F. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev. 1990, 42, 85-100.
43. Weber, M. M.; Lang, J.; Abedinpour, F.; Zeilberger, K.; Adelmann, B.; Engelhardt, D. Different inhibitory effect of etomidate and ketoconazole on the human adrenal steroid biosynthesis. Clin. Invest. 1993, 71, 933-938.
44. Ledingham, I. M.; Watt, I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983, 1, 1270.
45. Wagner, R. L.; White, P. F.; Kan, P. B.; Rosenthal, M. H.; Feldman, D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N. Engl. J. Med. 1984, 310, 1415-1421.
46. Diago, M. C.; Amado, J. A.; Otero, M.; Lopez-Cordovilla, J. J. Anti-adrenal action of subanaesthetic dose of etomidate. Anaesthesia 1988, 43, 644-645.
47. Belelli, D.; Lambert, J. J.; Peters, J. A.; Wafford, K.; Whiting, P. J. The interaction of the general anesthetic etomidate with the γ-aminobutyric acid type A receptor is influenced by a single amino acid. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 11031-11036.
48. Franks, N. P. Molecular targets underlying general anaesthesia. Br. J. Pharmacol. 2006, 147, S72-S81.
49. Hahner, S.; Stuermer, A.; Kreissl, M.; Reiners, C.; Fassnacht, M.; Hänscheid, H.; Beuschlein, F.; Zink, M.; Lang, K.; Zolle, I.; Allolio, B.; Schirbel, A. Unpublished results.
50. 18F-FETO with respect to the adrenocortical and GABAergic system in rats. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 1398-1401.
51. Eriksson, B.; Bergström, M.; Sundin, A.; Juhlin, C.; Örlefors, H.; Öberg, K.; Långström, B. The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann. N.Y. Acad. Sci. 2002, 970, 159-169.
52. 11C-metomidate PET imaging of adrenocortical cancer. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 403-410.
53. 18F-FDG. J. Nucl. Med. 2004, 45, 972-979.
54. 11C-metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J. Clin. Endocrinol. Metab. 2006, 91, 1410-1414.
55. 18F-FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. Eur. J. Nucl. Med. Mol. Imaging 2006, 33, 669-672.
56. Mikenda, W. Solid films and layers deposited on silicon - a versatile infrared sampling technique. Vib. Spectrosc. 1992, 3, 327-330.
57. Kitamura, M.; Oka, H.; Noyori, R. Asymmetric addition of dialkylzincs to benzaldehyde derivatives catalyzed by chiral β-amino alcohols. Evidence for the monomeric alkylzinc aminoalkoxide as catalyst. Tetrahedron 1999, 55, 3605-3614.
58. Mueller-Vieira, U.; Angotti, M.; Hartmann, R. W. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11β-hydroxylase) inhibitors. J. Steroid Biochem. Mol. Biol. 2005, 96, 259-270.